Gene editing is transforming the treatment of inherited diseases, but efficient and precise gene insertion has often come at the expense of cell viability, stem cell fitness, and long-term durability.…
Touchlight’s cell-free DNA platform offers a fundamentally different approach to DNA manufacturing—enabling the rapid, scalable, and high-quality production of enzymatically produced DNA for advanced therapies. At the core of this…
Touchlight’s Chief Scientific Officer, Dr. Jill Makin, discusses how the rapid evolution of advanced therapeutics is reshaping the industry, and why cell‑free DNA is has emerged as a foundational technology…
This application note evaluates the in vivo performance of Touchlight’s doggybone DNA™ (dbDNA™) compared with conventional plasmid DNA when delivered using Sartorius Polyplus non‑viral delivery reagents. The study investigates how…
Discover how Touchlight’s novel circular DNA architectures—mbDNA™, sscDNA, hsscDNA, and dscDNA—enable precise, efficient gene insertion for next‑generation gene editing and non‑viral gene therapy.
Plasmid DNA has long been the workhorse of cell and gene therapy — supporting countless clinical programs and enabling many of the field’s most important breakthroughs. At the same time,…
How AI Assisted Bioprocessing Can Transform Biotech Biotechnology is evolving, but some methods haven’t caught up. Slow experiments, costly materials, and outdated assumptions are holding back innovation. As demand…
Touchlight today announced the expansion of its groundbreaking mbDNA™ platform with the introduction of three new circular DNA architectures: sscDNA, hsscDNA, and dscDNA.